A new paradigm has emerged for osteogenesis imperfecta as a collagen-related disorder.
The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by …

Background Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal
type I collagen bone matrix which typically results in multiple fractures with little or no …

Abstract Purpose of Review Osteogenesis imperfecta (OI) is a genetic bone disorder
resulting in bone fragility. It has a heterogeneous phenotype which typically includes …

We analyzed women and newborn outcome after maternal exposure to BPs. BPs have no
teratogenic effect on the 36 analyzed pregnancies compared to unexposed controls …

Abstract Background/Aims: To systematically assess contemporary knowledge regarding the
effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta …

In a large cohort of osteogenesis imperfecta type V (OI type V) patients (17 individuals from
12 families), we identified the same mutation in the 5′ untranslated region (5′ UTR) of the …

Osteogenesis imperfecta (OI) is characterized by extremely brittle bone. Currently,
bisphosphonate drugs allow a decrease of fracture by inhibiting bone resorption and …

Osteogenesis imperfecta type III (OI) is a serious genetic condition with poor bone quality
and a high fracture rate in children. In a previous study, it was shown that a monoclonal …

Objective Several studies investigated the association between bisphosphonate use and the
risk of implant revision after total hip or knee arthroplasty (THA or TKA); However, the …

The effect of bisphosphonate treatment on bone mineral density (BMD) and fracture rates
was assessed in adults with osteogenesis imperfecta (OI). This observational …